Testing the antidepressant properties of the peptide ARA290 in a human neuropsychological model of drug action

What Was Tested

Researchers studied ARA-290 in this randomized controlled trial publication.

The aim of this study was to investigate the possible antidepressant effects of ARA290 in a neuropsychological model of drug action.

Why It Was Studied

Studies on the neural effects of Erythropoietin (EPO) indicate that EPO may have antidepressant effects.

Due to its hematopoietic effects, EPO may cause serious side-effects with repeated administration if patients are not monitored extensively.

Who Took Part

The age groups tagged for this paper are teenagers, young adults and adults, both men and women.

How the Study Was Run

The design is described as randomized, double-blind, placebo-controlled and parallel-group.

The participants were allocated by chance, so the ARA-290 group and the comparison group should start out alike.

Neither the participants nor the staff measuring them knew who was on ARA-290, so expectations could not easily colour the readings.

The comparison arm used a placebo, so changes seen with ARA-290 could be set against what happens without it.

Groups ran in parallel: each of the participants stayed in one arm throughout.

Neural and cognitive effects were assessed one week after administration.

What Was Measured

Primary outcome measures were the neural processing of fearful vs happy faces and the behavioral recognition of emotional facial expressions.

PubMed files the paper under topics including Analysis of Variance, Antidepressive Agents, Brain, Cognition, Emotions, Facial Expression and Image Processing, Computer-Assisted.

The authors tagged it with the keywords ARA290, Antidepressants, Erythropoietin and Neuropsychological model of drug action.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of ARA-290.

The publication is from 2015 (European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology), a journal based in Netherlands.

More context: the ARA-290 compound page, all human trials.